图书简介
This book covers a comprehensive update on acute and chronic leukemia. In 54 chapters, authors introduce research progress and clinical trials of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and chronic myeloid leukemia (CML). The last decade has seen the integration of genetic and clinical information to determine the prognosis and treatment strategies.This book provides practitioners, researchers and graduate students of Hematology and Hematopathology a comprehensive update on the pathobiology, genomics, classification, diagnosis, monitoring, prognostication and therapy of both acute and chronic leukemias.
Ch 1 Basic haematopoiesis and leukemia stem cells.- Ch 2 Modern classification of acute and chronic leukemias: integrating biology, clinicopathologic features and genomics.- Ch 3 Molecular techniques in the diagnosis and monitoring of acute and chronic leukemias.- Ch 4 Flow cytometric techniques in the diagnosis and monitoring of acute leukemias.- Ch 5 Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia.- Ch 6 Frontline management of acute myeloid leukaemia eligible for intensive chemotherapy.- Ch 7 Frontline management of elderly acute myeloid leukemia ineligible for intensive treatment.- Ch 8 Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia.- Ch 9 Management of relapsed or refractory AML.- Ch 10 The Role of BCL-2 / MCL-1 targeting in Acute Myeloid Leukemia.- Ch 11 Role of IDH1/IDH2 inhibitors in AML.- Ch 12 Next-generation FLT3 inhibitors for the treatment of FLT3-positive AML.- Ch 13 Allogeneic hematopoietic stem cell transplantation for AML.- Ch 14 Maintenance therapy following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.- Ch 15 Immunotherapeutic targeting of AML.- Ch 16 In the pipeline – Emerging therapy for acute myeloid leukaemia.- Ch 17 Frontline management of acute promyelocytic leukemia.- Ch 18 Management of relapsed acute promyelocyticleukemia and the role of hematopoietic stem cell transplantation.- Ch 19 Genomic Landscape of Acute Lymphoblastic Leukaemia (ALL) – Insights to Leukaemogenesis, Prognostications and Treatment.- Ch 20 Management of adolescent and young adults with Acute Lymphoblastic Leukaemia.- Ch 21 Management of older patients with acute lymphoblastic leukemia.- Ch 22 Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia.- Ch 23 Management of Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (Ph-like ALL).- Ch 24 Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia.- Ch 25 Immunotherapy for ALL.- Ch 26 In the Pipeline - Emerging therapy for ALL.- Ch 27 Inherited/genetic predisposition to MDS and AML.- Ch 28 Clonal hematopoiesis and its functional implications in MDS/AML.- Ch 29 Therapy-related MDS/AML and the role of environmental factors.- Ch 30 Prognostic indicators in MDS and CMML.- Ch 31 Treatment algorithm of myelodysplastic syndromes.- Ch 32 Treatment algorithm of CMML and other uncommon MDS/MPN subtypes.- Ch 33 Novel strategies to manage cytopenia in low-risk MDS.- Ch 34 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: when and how?.- Ch 35 In the Pipeline - Emerging therapy for MDS and MDS/MPN.- Ch 36 Molecular landscape and personalized prognostic prediction of MPNs.- Ch 37 Treatment algorithm of polycythemia Vera.- Ch 38 Treatment algorithm of essential thrombocythemia.- Ch 39 Prognostic models for primary and secondary myelofibrosis.- Ch 40 Treatment algorithm for primary and secondary myelofibrosis.- Ch 41 Diagnosis and management of prefibrotic primary myelofibrosis (pre-PMF).- Ch 42 Interferons In myeloproliferative neoplasms.- Ch 43 JAK inhibitors for the management of myeloproliferative neoplasms.- Ch 44 Allogeneic hematopoietic stem cell transplantation for myelofibrosis – when and how?.- Ch 45 Thrombosis and myeloproliferative neoplasms.- Ch 46 Eosinophilic disorders and systemic mastocytosis.- Ch 47 In the Pipeline - Emerging therapy for classical Ph-negative MPNs.- Ch 48 Current guidelines and treatment algorithm of chronic myeloid leukaemia.- Ch 49 Treatment-free remission in chronic myeloid leukemia.- Ch 50 Treatment options in CML resistant or intolerant to second-generation tyrosine kinase inhibitors.- Ch 51 Allogeneic hematopoietic cell transplantation in CML: when and how?.- Ch 52 In the Pipeline - Emerging therapy for CML.Ch 1 Basic haematopoiesis and leukemia stem cells.- C
Trade Policy 买家须知
- 关于产品:
- ● 正版保障:本网站隶属于中国国际图书贸易集团公司,确保所有图书都是100%正版。
- ● 环保纸张:进口图书大多使用的都是环保轻型张,颜色偏黄,重量比较轻。
- ● 毛边版:即书翻页的地方,故意做成了参差不齐的样子,一般为精装版,更具收藏价值。
关于退换货:
- 由于预订产品的特殊性,采购订单正式发订后,买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性,发生以下情况的,请直接拒收货物,由快递返回:
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全(例如:光盘等)
并请在工作日通过电话400-008-1110联系我们。
- 签收后,如发生以下情况,请在签收后的5个工作日内联系客服办理退换货:
- ● 缺页/错页/错印/脱线
关于发货时间:
- 一般情况下:
- ●【现货】 下单后48小时内由北京(库房)发出快递。
- ●【预订】【预售】下单后国外发货,到货时间预计5-8周左右,店铺默认中通快递,如需顺丰快递邮费到付。
- ● 需要开具发票的客户,发货时间可能在上述基础上再延后1-2个工作日(紧急发票需求,请联系010-68433105/3213);
- ● 如遇其他特殊原因,对发货时间有影响的,我们会第一时间在网站公告,敬请留意。
关于到货时间:
- 由于进口图书入境入库后,都是委托第三方快递发货,所以我们只能保证在规定时间内发出,但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间:
- 010-68433105/3213正常接听咨询电话的时间为:周一至周五上午8:30~下午5:00,周六、日及法定节假日休息,将无法接听来电,敬请谅解。
- 其它时间您也可以通过邮件联系我们:customer@readgo.cn,工作日会优先处理。
关于快递:
- ● 已付款订单:主要由中通、宅急送负责派送,订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐